UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 45

Sortiert nach

Safety and Efficacy: Clinical Experience of Venetoclax in Combination With Hypomethylating Agents in Both Newly Diagnosed and Relapsed/Refractory Advanced Myeloid Malignancies

HemaSphere, 2021-04, Vol.5 (4), p.e549-n/a

2021

Volltextzugriff (PDF)

Ascertaining QUAZARs: slow-motion and light-speed development of oral azacitidine and decitabine

Leukemia & lymphoma, 2023-02, Vol.64 (3), p.525-539

2023

Volltextzugriff (PDF)

Myelodysplastic syndromes: a review of therapeutic progress over the past 10 years

Expert review of anticancer therapy, 2020-06, Vol.20 (6), p.465-482

2020

Volltextzugriff (PDF)

Myelo-deception: Luspatercept & TGF-Beta ligand traps in myeloid diseases & anemia

Leukemia research, 2020-10, Vol.97, p.106430-106430, Article 106430

2020

Volltextzugriff (PDF)

Forsaken Pharmaceutical: Glasdegib in Acute Myeloid Leukemia and Myeloid Diseases

Clinical lymphoma, myeloma and leukemia, 2021-04, Vol.21 (4), p.e415-e422

2021

Volltextzugriff (PDF)

Rigosertib in combination with azacitidine in patients with myelodysplastic syndromes or acute myeloid leukemia: Results of a phase 1 study

Leukemia research, 2020-07, Vol.94, p.106369-106369, Article 106369

2020

Volltextzugriff (PDF)

A phase 1/2 study of rigosertib in patients with myelodysplastic syndromes (MDS) and MDS progressed to acute myeloid leukemia

Leukemia research, 2018-01, Vol.64, p.10-16

2018

Volltextzugriff (PDF)

The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes

Expert review of anticancer therapy, 2016-08, Vol.16 (8), p.805-810

2016

Volltextzugriff (PDF)

Safety and efficacy of azacitidine in elderly patients with intermediate to high-risk myelodysplastic syndromes

Therapeutic Advances in Hematology, 2017-01, Vol.8 (1), p.21-27

2017

Volltextzugriff (PDF)

A 60-Year-Old Male With Synchronous Acute Myeloid Leukemia and Metastatic Adenocarcinoma of the Pancreas

Seminars in oncology, 2014-12, Vol.41 (6), p.e51-e59

2014

Volltextzugriff (PDF)

Management of Chemotherapy-Induced Neutropenic Fever

Hospital Practice, 2013-02, Vol.41 (1), p.96-108

2013

Volltextzugriff (PDF)

Clinical Significance of Cytogenetic Manifestations in Myelodysplastic Syndromes

Laboratory medicine, 2013-03, Vol.44 (2), p.103-107

2013

Volltextzugriff (PDF)

Therapeutic Modalities for Patients with Lower-Risk Myelodysplastic Syndromes: Current Options and Future Directions

Current hematologic malignancy reports, 2011-03, Vol.6 (1), p.5-12

2011

Volltextzugriff (PDF)

Therapeutic Options in Myelodysplastic Syndromes Following Hypomethylating Agent Failure

EMJ Hematology, 2020-01, p.52-64

2020

Volltextzugriff (PDF)

T-Cell Mediated Cytopenias in Patients with Myelodysplastic Syndromes Respond to Intravenous Immunoglobulin

Blood, 2019-11, Vol.134 (Supplement_1), p.4260-4260

2019

Volltextzugriff (PDF)

T-Cell Monoclonality As Assessed By TCR-Sequencing: A Potential Biomarker of Response in Patients with MDS with Autoimmune Cytopenias Treated with IVIG

Blood, 2020-11, Vol.136 (Supplement 1), p.8-9

2020

Volltextzugriff (PDF)

Myelodysplastic Syndromes (MDS) & COVID-19: Clinical Experience from the US Epicenter of the Pandemic

Blood, 2020-11, Vol.136 (Supplement 1), p.17-18

2020

Volltextzugriff (PDF)

Combination of Ras Modulator and Azacitidine Impacts Innate Immune Signaling Pathway in MDS-L Cell Line

Blood, 2021-11, Vol.138 (Supplement 1), p.4325-4325

2021

Volltextzugriff (PDF)

The Sequenced Combination of Rigosertib and Azacitidine Has Modulatory Effects on CXCL8, RIG-I like Receptor (RLR) and Wnt/β-Catenin Signaling and Downstream Hematopoiesis Pathways in an in Vitro Model of the Myelodysplastic Syndrome

Blood, 2019-11, Vol.134 (Supplement_1), p.4231-4231

2019

Volltextzugriff (PDF)

Rigosertib in Combination with Azacitidine Impacts Metabolic and Differentiation Pathways in the MDS-L Cell Line

Blood, 2020-11, Vol.136 (Supplement 1), p.35-36

2020

Volltextzugriff (PDF)

Abstract 3026: Rigosertib (RIG) modulates MAPK and hematopoiesis signaling and synergizes Azacitidine (AZA) altering viral mimicry pathway in myelodysplastic syndrome (MDS)

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.3026-3026

2019

Volltextzugriff (PDF)

Truncation Products of Stromal Cell Derived Factor-1 (CXCL12) Quantified By Mass Spectrometry in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Treated with Rigosertib in a Phase I-II Study

Blood, 2018-11, Vol.132 (Supplement 1), p.1357-1357

2018

Volltextzugriff (PDF)

Sequential Treatment with Rigosertib Followed By Azacitidine Maximizes the Effects on the Interferon Signaling Pathway in Hematopoietic Cells in Myelodysplastic Syndrome (MDS)

Blood, 2018-11, Vol.132 (Supplement 1), p.5500-5500

2018

Volltextzugriff (PDF)

Cross Talk between the Immune Compartment and the Tumor Cells in Myelodysplastic Syndromes (MDS)

Blood, 2019-11, Vol.134 (Supplement_1), p.2986-2986

2019

Volltextzugriff (PDF)

Effects of Rigosertib (RIGO) Alone or in Combination with Azacitidine or Vorinostat on Epigenetic Reprogramming of CD34+ Cells in the Myelodysplastic Syndrome

Blood, 2017-12, Vol.130, p.4235-4235

2017

Volltextzugriff (PDF)

1 – 25 von 45

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(44)
Mit Volltextzugriff
(44)

Publikationsform

Artikel
(44)
Buchkapitel
(1)

Sprache

Englisch
(45)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(12)
Science & Technology
(12)
Hematology
(9)
Humans
(9)
Myelodysplastic Syndromes
(8)
Oncology
(8)
Acute Myeloid Leukemia
(5)
Hypomethylating Agents
(4)
Myelodysplastic Syndrome
(4)
Animals
(3)
Azacitidine
(3)
Azacitidine - Therapeutic Use
(3)
Decitabine
(3)
Myelodysplastic Syndromes - Drug Therapy
(3)
Myelodysplastic Syndromes - Pathology
(3)
Rigosertib
(3)
Bone Marrow
(2)
Combined Modality Therapy
(2)
Disease Progression
(2)
Dna Methyltransferase Inhibitors
(2)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Safety and Efficacy: Clinical Experience of Venetoclax in Combination With Hypomethylating Agents in Both Newly Diagnosed and Relapsed/Refractory Advanced Myeloid Malignancies

Ascertaining QUAZARs: slow-motion and light-speed development of oral azacitidine and decitabine

Myelodysplastic syndromes: a review of therapeutic progress over the past 10 years

Myelo-deception: Luspatercept & TGF-Beta ligand traps in myeloid diseases & anemia

Forsaken Pharmaceutical: Glasdegib in Acute Myeloid Leukemia and Myeloid Diseases

Rigosertib in combination with azacitidine in patients with myelodysplastic syndromes or acute myeloid leukemia: Results of a phase 1 study

A phase 1/2 study of rigosertib in patients with myelodysplastic syndromes (MDS) and MDS progressed to acute myeloid leukemia

The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes

Safety and efficacy of azacitidine in elderly patients with intermediate to high-risk myelodysplastic syndromes

A 60-Year-Old Male With Synchronous Acute Myeloid Leukemia and Metastatic Adenocarcinoma of the Pancreas

Management of Chemotherapy-Induced Neutropenic Fever

Clinical Significance of Cytogenetic Manifestations in Myelodysplastic Syndromes

Therapeutic Modalities for Patients with Lower-Risk Myelodysplastic Syndromes: Current Options and Future Directions

Therapeutic Options in Myelodysplastic Syndromes Following Hypomethylating Agent Failure

T-Cell Mediated Cytopenias in Patients with Myelodysplastic Syndromes Respond to Intravenous Immunoglobulin

T-Cell Monoclonality As Assessed By TCR-Sequencing: A Potential Biomarker of Response in Patients with MDS with Autoimmune Cytopenias Treated with IVIG

Myelodysplastic Syndromes (MDS) & COVID-19: Clinical Experience from the US Epicenter of the Pandemic

Combination of Ras Modulator and Azacitidine Impacts Innate Immune Signaling Pathway in MDS-L Cell Line

The Sequenced Combination of Rigosertib and Azacitidine Has Modulatory Effects on CXCL8, RIG-I like Receptor (RLR) and Wnt/β-Catenin Signaling and Downstream Hematopoiesis Pathways in an in Vitro Model of the Myelodysplastic Syndrome

Rigosertib in Combination with Azacitidine Impacts Metabolic and Differentiation Pathways in the MDS-L Cell Line

Abstract 3026: Rigosertib (RIG) modulates MAPK and hematopoiesis signaling and synergizes Azacitidine (AZA) altering viral mimicry pathway in myelodysplastic syndrome (MDS)

Truncation Products of Stromal Cell Derived Factor-1 (CXCL12) Quantified By Mass Spectrometry in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Treated with Rigosertib in a Phase I-II Study

Sequential Treatment with Rigosertib Followed By Azacitidine Maximizes the Effects on the Interferon Signaling Pathway in Hematopoietic Cells in Myelodysplastic Syndrome (MDS)

Cross Talk between the Immune Compartment and the Tumor Cells in Myelodysplastic Syndromes (MDS)

Effects of Rigosertib (RIGO) Alone or in Combination with Azacitidine or Vorinostat on Epigenetic Reprogramming of CD34+ Cells in the Myelodysplastic Syndrome

Suchergebnisse filtern